Dassault Systèmes: Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes

Rhea-AI Summary

Medidata, a Dassault Systèmes company, has expanded its partnership with Horizon Therapeutics to enhance clinical trial efficiencies across various therapeutic areas such as ophthalmology, rheumatology, and nephrology. The collaboration builds on a successful relationship that began in 2017. Medidata will provide Horizon with an extensive suite of clinical trial solutions, including the Medidata Rave Clinical Cloud and Intelligent Trials, which utilizes AI for data analytics and performance metrics. This partnership is expected to facilitate faster completion of clinical studies and improve overall trial management.

Positive

• Expanded partnership with Horizon Therapeutics to enhance clinical trial efficiencies.
• Access to Medidata's comprehensive suite of clinical trial solutions.
• Utilization of AI and advanced analytics for better trial planning and execution.

Negative

• None.

New agreement builds on previous success in speeding study start-up and completion

New York, New York – February 4, 2021 – Medidata, a Dassault Systèmes company and the global leader in creating end-to-end solutions to support the entire clinical development process, today announced its expanded partnership with Horizon Therapeutics plc (NASDAQ: HZNP). Starting in 2017 with one technology solution, Medidata will now provide a diverse suite of solutions for Horizon’s clinical research needs in multiple therapeutic areas including ophthalmology, rheumatology, and nephrology.

“We’re delighted to be a key partner to Horizon and its exceptional journey that benefits patients by advancing science and treatments,” said Tarek Sherif, co-founder and co-CEO, Medidata. “Medidata’s goal is to facilitate Horizon’s path forward using advanced analytics and technology. We’re looking forward to further supporting the company’s vision, especially as it relates to improving efficiencies and speeding the completion of clinical studies.”

Horizon will access a broad range of clinical trial solutions using the Medidata Rave Clinical Cloud^TM, the industry’s most used platform to accelerate clinical research with a suite of applications including data capture, data management, trial planning, and trial management. In addition, Horizon will use Medidata’s Intelligent Trials product, which brings artificial intelligence (AI), partnered with advanced analytics, to bring cross-industry real-time performance metrics, predictive models, and forecasting capabilities for trial planning and execution. Intelligent Trials, provided by Acorn AI, Medidata’s data and analytics solutions, is built on the industry’s broadest clinical trial dataset, covering more than six million patients in 22,000+ clinical trials.

“Through the use of the Medidata technologies, we have been able to create a more efficient, manageable and cost-effective clinical trial process, which led us to expand this productive relationship,” said Karin Rosén, M.D., Ph.D., executive vice president research and development and chief scientific officer, at Horizon. “As our clinical needs have evolved, the Medidata platform gives us the flexibility and agility to scale and grow.”

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,600+ customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata, The Operating System for Life Sciences^TM.

Medidata is a registered trademark of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systèmes.

About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual experience twins of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systèmes brings value to more than 290,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, EXALEAD, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

About Horizon
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

Contact
Caroline Drucker
Senior Director, Head of Corporate Communications
+1-347-675-3222
cdrucker@medidata.com

Paul Oestreicher
External Communications Director
+1-917-522-4692
poestreicher@medidata.com

Attachment

• Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes

FAQ

What is the focus of the expanded partnership between Medidata and Horizon Therapeutics?

The partnership aims to enhance clinical trial efficiencies in areas such as ophthalmology, rheumatology, and nephrology.

When did the partnership between Medidata and Horizon Therapeutics begin?

The partnership started in 2017 with a single technology solution.

What technologies will Medidata provide to Horizon Therapeutics?

Medidata will provide a range of clinical trial solutions, including the Medidata Rave Clinical Cloud and Intelligent Trials, which incorporates AI for advanced analytics.

How does the partnership between Medidata and Horizon benefit clinical trials?

The partnership is expected to streamline trial processes, improve efficiencies, and accelerate the completion of clinical studies.

What sectors will benefit from this partnership?

The partnership will focus on multiple therapeutic areas, including ophthalmology, rheumatology, and nephrology.